PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Royal Derby Hospital Centre, University of Nottingham, Derby, UK.\', \'MRC-Versus Arthritis Centre for Musculoskeletal Ageing Research, NIHR, Nottingham BRC, University of Nottingham, Nottingham, UK.\', \'Department of Endocrinology and Diabetes, University Hospitals Derby and Burton NHS Foundation Trust, Derby, UK.\']
?:citedBy
  • -1
?:creator
?:doi
  • 10.1080/03007995.2022.2027141
?:doi
?:hasPublicationType
?:journal
  • Current medical research and opinion
is ?:pmid of
?:pmid
?:pmid
  • 35057687
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 0.944
?:rankingScore_hIndex
  • 96
is ?:relation_isRelatedTo_publication of
?:title
  • Can sodium-glucose co-transporter-2 (SGLT-2) inhibitor reduce the risk of adverse complications due to COVID-19? - Targeting hyperinflammation.
?:type
?:year
  • 2022

Metadata

Anon_0  
expand all